antitrust claim against Suboxone, including false advertising, survives summary judgment
43(B)log
AUGUST 25, 2022
22, 2022) The court here allows an antitrust claim to proceed based in part on allegedly false/misleading statements because they form part of the alleged anticompetitive product-hopping scheme and because the unique characteristics of the drug market make market-based responses to false advertising difficult.
Let's personalize your content